Kingswood Wealth Advisors LLC Invests $229,000 in Becton, Dickinson and Company (NYSE:BDX)

Kingswood Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 925 shares of the medical instruments supplier’s stock, valued at approximately $229,000.

Several other large investors have also made changes to their positions in BDX. Mcdonald Partners LLC raised its stake in Becton, Dickinson and Company by 1.1% during the first quarter. Mcdonald Partners LLC now owns 5,966 shares of the medical instruments supplier’s stock worth $1,476,000 after purchasing an additional 63 shares during the period. Security National Bank raised its position in shares of Becton, Dickinson and Company by 18.3% during the 1st quarter. Security National Bank now owns 408 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 63 shares during the period. DLK Investment Management LLC lifted its holdings in Becton, Dickinson and Company by 7.8% in the first quarter. DLK Investment Management LLC now owns 18,174 shares of the medical instruments supplier’s stock valued at $4,497,000 after acquiring an additional 1,320 shares during the last quarter. Fermata Advisors LLC grew its position in Becton, Dickinson and Company by 12.0% in the first quarter. Fermata Advisors LLC now owns 1,238 shares of the medical instruments supplier’s stock worth $306,000 after acquiring an additional 133 shares during the period. Finally, Jacobs & Co. CA increased its stake in Becton, Dickinson and Company by 1.0% during the first quarter. Jacobs & Co. CA now owns 47,939 shares of the medical instruments supplier’s stock worth $11,862,000 after acquiring an additional 456 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the sale, the executive vice president now directly owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,615 shares of company stock worth $2,033,381. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. Barclays upped their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Finally, StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $280.17.

Becton, Dickinson and Company Stock Up 1.2 %

Shares of NYSE:BDX opened at $233.71 on Friday. The firm has a market capitalization of $67.54 billion, a PE ratio of 51.48, a price-to-earnings-growth ratio of 2.02 and a beta of 0.44. Becton, Dickinson and Company has a 1 year low of $224.00 and a 1 year high of $287.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The firm’s 50-day moving average is $234.36 and its two-hundred day moving average is $237.85.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.86 earnings per share. Analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Monday, June 10th were paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date was Monday, June 10th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.